Invasive Ductal Carcinoma (IDC)

What invasive ductal carcinoma means

The breast is made of lobules, which produce milk, and ducts, which carry it to the nipple. "Ductal" means the cancer arose from the cells lining the ducts. "Invasive" (or infiltrating) means it has broken through the duct wall, so cells can reach lymph and blood vessels and potentially spread.

This distinguishes it from ductal carcinoma in situ (DCIS), where the abnormal cells are still contained inside the ducts (stage 0). It also differs from invasive lobular carcinoma, which starts in the lobules, grows in single-file strands and is harder to see on mammograms.

Pathologists now often call IDC invasive breast carcinoma of no special type (NST), because it lacks the patterns of rarer special types such as tubular, mucinous, medullary-like or papillary carcinoma. For the overview of all breast cancers, see breast cancer.

Symptoms

Many IDCs are found on a screening mammogram before they can be felt. When symptoms occur, they include:

• a hard, painless lump with irregular edges, often fixed in place
• thickening or a change in breast size or shape
• skin dimpling or puckering, redness or orange-peel skin
• nipple inversion, scaling or bloody discharge
• a lump or swelling in the armpit

Most breast lumps are not cancer, but any new lump needs prompt assessment.

Risk factors

• Female sex and increasing age (most diagnoses after 50)
• Inherited gene variants, especially BRCA1 or BRCA2, PALB2, CHEK2, ATM
• Family history of breast or ovarian cancer
• Dense breast tissue, previous atypical hyperplasia or DCIS
• Longer lifetime estrogen exposure: early periods, late menopause, no pregnancies or first pregnancy after 30, combined hormone therapy after menopause
• Alcohol, obesity after menopause, inactivity
• Chest radiation at a young age

How IDC is diagnosed

1. Imaging: diagnostic mammogram and breast ultrasound; MRI in some cases (dense breasts, lobular features, high genetic risk, or to plan surgery).
2. Core needle biopsy: confirms invasive cancer and provides tissue for receptor testing.
3. Armpit ultrasound with biopsy of any suspicious lymph node.
4. Staging scans (CT, bone scan or PET-CT) for larger tumors, node-positive disease or symptoms suggesting spread.
5. Genetic testing for people with a strong family history, young age at diagnosis, triple-negative cancer or certain ancestry.

Understanding the pathology report

Grade

Grade describes how abnormal the cells look under the microscope (Nottingham score):

Receptor status and subtypes

HER2-low status (some HER2 but below the positive threshold) matters for advanced disease, where specific drugs can be used.

Other items

• Ki-67: proportion of dividing cells.
• Lymphovascular invasion: cancer cells seen in small vessels.
• Margins: whether cancer reached the edge of the removed tissue.
• Genomic tests (Oncotype DX, MammaPrint) for ER-positive, HER2-negative IDC help decide whether chemotherapy adds benefit.

Stages

Modern staging also folds in grade and receptor status, so two tumors of the same size can have different stages.

Treatment

A multidisciplinary team plans treatment. The order varies: some people have drug treatment first (neoadjuvant), particularly with HER2-positive or triple-negative IDC, to shrink the tumor and test how well it responds.

Surgery

• Lumpectomy (breast-conserving surgery) followed by radiation is as effective as mastectomy for most early IDC.
• Mastectomy, with or without reconstruction, for larger or multiple tumors, or by preference.
• Sentinel lymph node biopsy removes the first few armpit nodes; full axillary dissection is needed less often than before.

Radiation

Usually given after lumpectomy and after mastectomy in higher-risk cases. Some older women with small, low-risk, ER-positive tumors may safely skip radiation if they take hormone therapy.

Hormone therapy

For ER- or PR-positive IDC: tamoxifen, or an aromatase inhibitor (letrozole, anastrozole, exemestane) after menopause, usually for 5 to 10 years. Ovarian suppression is added for some younger women.

Chemotherapy, targeted therapy and immunotherapy

• Chemotherapy for higher-risk, HER2-positive and triple-negative cancers.
• HER2-targeted drugs: trastuzumab, pertuzumab, and trastuzumab emtansine if cancer remains after neoadjuvant treatment.
• CDK4/6 inhibitors (abemaciclib, ribociclib) for some high-risk ER-positive early cancers.
• Pembrolizumab with chemotherapy for higher-stage triple-negative IDC.
• Olaparib for some people with BRCA mutations.

Side effects to know about

Fatigue, hair loss with some chemotherapy, early menopause symptoms, joint aches with aromatase inhibitors, and arm swelling (lymphedema) after lymph node surgery or radiation.

Outlook

According to the American Cancer Society (SEER data), 5-year relative survival for breast cancer is about 99% when localized, about 86% with regional lymph node spread and about 31% when it has spread to distant organs. Outlook is best for small, low-grade, hormone receptor-positive tumors. HER2-positive cancers have improved dramatically with targeted drugs. ER-positive IDC can recur many years later, which is why hormone therapy continues for 5 years or more.

Follow-up

Expect regular checkups and a yearly mammogram of any remaining breast tissue. Routine scans or tumor marker tests are not recommended without symptoms. Report new bone pain, persistent cough, breathlessness, headaches or abdominal swelling.

Frequently asked questions

Is invasive ductal carcinoma curable?

Yes, in most cases when found before it has spread beyond the breast and nearby lymph nodes. Most people with stage I to III IDC are treated with curative intent. Stage IV IDC is not usually curable but can often be controlled for years with ongoing treatment.

Is invasive ductal carcinoma aggressive?

It varies. Grade 1, hormone receptor-positive IDC tends to grow slowly. Grade 3, HER2-positive and triple-negative IDC grow faster, but they often respond well to chemotherapy and targeted treatment. The pathology report, not the name IDC, tells you how aggressive a particular cancer is.

What is the difference between IDC and DCIS?

In DCIS, abnormal cells are confined inside the milk ducts and cannot spread (stage 0). In IDC, cells have broken through the duct wall into breast tissue and can reach lymph nodes and the bloodstream. IDC usually needs more extensive treatment than DCIS.

What is the survival rate for stage 1 invasive ductal carcinoma?

Stage I breast cancer has a 5-year relative survival rate close to 100% in the US. Long-term outcomes depend on receptor status and completing recommended treatment, especially hormone therapy for ER-positive cancers.

Do all people with IDC need chemotherapy?

No. Many people with small, ER-positive, HER2-negative IDC do not benefit from chemotherapy, and genomic tests such as Oncotype DX help identify them. Chemotherapy is more often recommended for larger, node-positive, high-grade, HER2-positive or triple-negative cancers.